RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia
Open Access
- 15 July 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (14) , 3597-3607
Abstract
Purpose: RNA splicing is a fundamental biological process that generates protein diversity from a finite set of genes. Recurrent somatic mutations of splicing factor genes are common in some hematologic cancers but are relatively uncommon in acute myeloid leukemia (AML, < 20% of patients). We examined whether RNA splicing differences exist in AML, even in the absence of splicing factor mutations. Experimental Design: We developed a bioinformatics pipeline to study alternative RNA splicing in RNA-sequencing data from large cohorts of patients with AML. Results: We have identified recurrent differential alternative splicing between patients with poor and good prognosis. These splicing events occurred even in patients without any discernible splicing factor mutations. Alternative splicing recurrently occurred in genes with specific molecular functions, primarily related to protein translation. Developing tools to predict the functional impact of alternative splicing on the translated protein, we discovered that approximately 45% of the splicing events directly affected highly conserved protein domains. Several splicing factors were themselves misspliced and the splicing of their target transcripts were altered. Studying differential gene expression in the same patients, we identified that alternative splicing of protein translation genes in ELNAdv patients resulted in the induction of an integrated stress response and upregulation of inflammation-related genes. Finally, using machine learning techniques, we identified a splicing signature of four genes which refine the accuracy of existing risk prognosis schemes and validated it in a completely independent cohort. Conclusions: Our discoveries therefore identify aberrant alternative splicing as a molecular feature of adverse AML with clinical relevance. See related commentary by Bowman, p. 3503Keywords
All Related Versions
Funding Information
- National Health and Medical Research Council (APP1163815)
- National Health and Medical Research Council (APP1024364, 1043934, 1102589)
- Wilhelm Sander Foundation (2013.086.2)
- Physician Scientists (G-509200-004)
- Deutsche Forschungsgemeinschaft (DFG SFB1243)
- BMBF (01ZZ1804B)
This publication has 47 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- hnRNP U Enhances Caspase-9 Splicing and Is Modulated by AKT-dependent Phosphorylation of hnRNP LJournal of Biological Chemistry, 2013
- Integrative Genome-wide Analysis Reveals Cooperative Regulation of Alternative Splicing by hnRNP ProteinsCell Reports, 2012
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaBlood, 2010
- iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolutionNature Structural & Molecular Biology, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Alternative isoform regulation in human tissue transcriptomesNature, 2008
- Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing SignalsJournal of Computational Biology, 2004